Published in Pharma Investments, Ventures and Law Weekly, May 16th, 2004
Revenues for the quarter were $766,530 as compared to revenues of $1,013,948 for the same period in fiscal 2003. There was a net loss of $566,001, or $0.07 per share, as compared to a net loss of $647,518, or $0.10 per share, for the second fiscal quarter of 2003. The decrease in revenues for the quarter ended March 31, 2004, is partly the result of a decrease in the recognition of deferred license fee revenue from a license and marketing agreement covering Combidex(C).
As a result of fluctuations in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly